| CAS NO: | 1609281-86-8 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| Molecular Weight (MW) | 441.5 |
|---|---|
| Formula | C21H23N5O4S |
| CAS No. | 1609281-86-8 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility(In vitro) | DMSO: 88 mg/mL (199.3 mM) |
| Water: <1 mg/mL | |
| Ethanol: 2 mg/mL (4.5 mM) | |
| Other Info | Chemical Name: 2-(Carbamoylamino)-5-[4-(3,5-dimethyl-1,2-oxazol-4-yl)-2-[(3S)-pyrrolidin-3-yloxy]phenyl]thiophene-3-carboxamide InChi Key: NMFIXEFNQPDISY-ZDUSSCGKSA-N InChi Code: InChI=1S/C21H23N5O4S/c1-10-18(11(2)30-26-10)12-3-4-14(16(7-12)29-13-5-6-24-9-13)17-8-15(19(22)27)20(31-17)25-21(23)28/h3-4,7-8,13,24H,5-6,9H2,1-2H3,(H2,22,27)(H3,23,25,28)/t13-/m0/s1 SMILES Code: O=C(C1=C(NC(N)=O)SC(C2=CC=C(C3=C(C)ON=C3C)C=C2O[C@@H]4CNCC4)=C1)N |
| Synonyms | AZD-3264; AZD3264; AZD 3264; |
| In Vitro | In vitroactivity: AZD3264, by inhibiting IKK2, was currently in preclinical development for the potential treatment of inflammatory diseases such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. Cell Assay: 1AZD3264, by inhibiting IKK2, was currently in preclinical development for the potential treatment of inflammatory diseases such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Org. Process Res. Dev. 2014, 18, 646–651. |
m.cnreagent.com
